1 - 10 of 68 Search Results for lumenis
|
|
2.
2002%20AR
(PAGE 75 OF 93)
|
|
|
... . The investments in corporate equity securities at September 30, 2002 and 2001 represent the fair value of our investment (5,432,099 shares) in Lumenis common stock and are classified as available for sale. The Lumenis common stock is unregistered and its trading is subject to restrictions under Securities ...
|
|
|
|
|
4.
2002%20AR
(PAGE 19 OF 93)
|
|
|
... associated with the acquisitions of DEOS and MicroLas. (5) Includes a $79.2 million, or $2.75 per diluted share, after-tax impairment charge on our Lumenis common stock, a $6.7 million, or $0.23 per diluted share, after-tax asset impairment charge resulting primarily from a decision to cease most of ...
|
|
|
|
|
5.
2002%20AR
(PAGE 20 OF 93)
|
|
|
... also recognized a loss of $104.2 million ($79.2 million after-tax) to reflect the other-than-temporary decline in market value of our investment in Lumenis common stock, acquired as a result of our April 2001 sale of our Medical segment to Lumenis. In fiscal 2001, we took the steps we considered necessary ...
|
|
|
|
|
6.
2002%20AR
(PAGE 21 OF 93)
|
|
|
completed the sale of our Medical segment to Lumenis, Inc. (formerly ESC Medical Systems Ltd.) for a combination of cash, notes and Lumenis common stock with an estimated value of $236.0 million plus a potential earnout of an additional $25.0 million. The sale resulted in a one-time after-tax gain ...
|
|
|
|
|
7.
Coherent_2007_accessible
(PAGE 77 OF 162)
|
|
|
... Stockholders' equity . $770,986 $717,504 $639,670 $588,704 $543,140 (1) Includes a $10.2 million after-tax impairment charge on our investment in Lumenis common stock; a $9.2 million after tax charge related to the termination of activities in our Telecom-Actives group; a $7.9 million after-tax charge ...
|
|
|
|
|
8.
Coherent_accessible
(PAGE 106 OF 156)
|
|
|
... . In the United States, we established a valuation allowance related to capital loss carryforwards generated from the disposal of our investment in Lumenis common stock. As of September 30, 2005, we maintained a valuation allowance of $15.8 million and $5.4 million for the federal and state tax benefits ...
|
|
|
|
|
9.
Coherent_accessible
(PAGE 107 OF 156)
|
|
|
... and general legal expenses) are included in Corporate and Other in the reconciliation of operating results. Furthermore, the write-downs of our Lumenis investment, interest expense, interest income, gains and losses on our deferred compensation plan assets and the gain on the sale of real estate are ...
|
|
|
|
|
10.
2002%20AR
(PAGE 25 OF 93)
|
|
|
... from income of $8.8 million to an expense of $97.4 million. Fiscal 2002 includes a $104.2 million charge due to the write-down of our investment in Lumenis common stock (investment write-down) due to an other-than-temporary impairment. Exclusive of the investment writedown, other income, net of other ...
|
|
Coherent Contact Information